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A B S T R A C T   
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2020 
and coronavirus disease 19 (COVID-19) was later announced as pandemic by the World Health Organization 
(WHO). Since then, several studies have been conducted on the prevention and treatment of COVID-19 by po-
tential vaccines and drugs. Although, the governments and global population have been attracted by some 
vaccine production projects, the presence of SARS-CoV-2-specific antiviral drugs would be an urge necessity in 
parallel with the efficient preventive vaccines. Various nonspecific drugs produced previously against other 
bacterial, viral, and parasite infections were recently evaluated for treating patients with COVID-19. In addition 
to therapeutic properties of these anti-COVID-19 compounds, some adverse effects were observed in different 
human organs as well. Not only several attentions were paid to antiviral therapy and treatment of COVID-19, but 
also nanomedicine, immunotherapy, and cell therapy were conducted against this viral infection. In this review 
study, we planned to introduce the present and potential future treatment strategies against COVID-19 and define 
the advantages and disadvantages of each treatment strategy.   
1. Introduction 
Human coronavirus 229E (HCoV-229E) (classified in the genus 
Alphacoronavirus) and HCoV-OC43 (Betacoronavirus lineage 2a mem-
ber) identified in the 1960s. Then in March 2003, severe acute respi-
ratory syndrome coronavirus 1 (SARS-CoV-1) (Betacoronavirus lineage 
2b member) appeared, while human coronavirus NL63 (HCoV-NL63) 
(Alphacoronavirus lineage 1b member) characterized in 2004, HCoV- 
HKU1 (Betacoronavirus lineage 2a member) discovered in 2005, and 
at last Middle East respiratory syndrome coronavirus (MERS-CoV) 
emerged in 2012 (Betacoronavirus lineage 2c member). Further exper-
imental and clinical studies revealed that CoVs including SARS-CoVs 
and MERS-CoV are the threat agents for great public health [1]. Since 
the sudden outbreak of coronavirus disease 2019 (COVID-19) by severe 
acute respiratory syndrome coronavirus (SARS-CoV-2) as the causative 
agent in Wuhan, China, in December 2020, the disease was spread 
rapidly around the world [2]. Immediately and on March 11, 2020, the 
World Health Organization (WHO) declared the COVID-19 outbreak as a 
pandemic viral infection [3]. SARS-CoV-2, is the seventh human coro-
navirus described to date as the etiological agent of COVID-19 charac-
terized by a pulmonary infection in humans [4]. Within this regard, 
evidence was rapidly reported that the patients are being affected by an 
infection with a novel betacoronavirus, which was nominated as 
SARS-CoV-2 [5–7], which represents a pandemic threat to global public 
health [7]. The sequence of novel SARS-CoV-2 has been shown to be 
75–80% identical to SARS-CoV-1% and 40% identical to MERS-CoV [8]. 
SARS-CoV-2 and SARS-CoV-1 share the same host receptor, human 
angiotensin-converting enzyme 2 (ACE2), which is the primary target of 
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the virus. The virus binding to the lung epithelial cells with ACE2 re-
ceptors and fusion with the cell membrane are the first steps of viral 
infection [9]. 
The coronavirus disease 2019 (COVID-19) pandemic passed all 
borders and has spread to almost all countries of the world [10]. At the 
time of publication (March 2021), there have been more than 118,000, 
000 people have been infected with the virus and more than 2,620,000 
deaths have been reported [11]. 
Generally, coronavirus-infecting human can be classified into low 
and highly pathogenic CoVs. Low pathogenic CoVs infect upper airway 
and cause seasonal respiratory illness, while highly pathogenic CoVs 
such as severe acute respiratory syndrome CoV (SARS-CoV) and Middle 
East respiratory syndrome CoV (MERS-CoV), infect the lower respira-
tory tract and may lead to acute respiratory distress syndrome (ARDS) 
and acute lung injury (ALI), and even death [12]. SARS-CoV-2 infection 
disrupts normal immune responses, leading to cytokine storm with 
various local and systematic damage of tissues and organs [13]. Local 
damages primarily affect the lower respiratory tract and present as 
pneumonia with the associated symptoms including fever, cough, 
expectoration, and hemoptysis. In addition to pulmonary damages of 
COVID-19, the incidence of other symptoms are occurred, includes 
heartbeat arrhythmia, hepatocellular injury, acute kidney injury, 
myocardial dysfunction, neurological illnesses, and gastrointestinal 
symptoms [14]. 
There are numerous potential approaches to prevent or treat COVID- 
19 such as vaccines, monoclonal antibodies, small-molecule drugs, 
interferon therapies, peptides, and oligonucleotides. Medications are 
being developed to target the spike, membrane, nucleocapsid, or enve-
lope proteins. For individuals exhibiting signs of the disease, including 
cough, fever, fatigue, rhinitis, and other symptoms typically begin to 
manifest after few days. About 75% of COVID-19 patients exhibit 
symptoms as diagnosed by computed tomography scan (CT scan). In 
COVID-19 infection, the pneumonia frequently presents in patients 
during the second or third week of symptomatic so the main symptoms 
of viral pneumonia include ground glass abnormalities, interlobular 
involvement, alveolar exudates, decreased oxygen saturation, blood gas 
deviations, and patchy consolidation. Lymphopenia is frequently 
observed together with an elevation in proinflammatory cytokines and 
inflammatory proteins such as C-reactive protein or CRP. Although, 
mechanical ventilators are used for patients with pulmonary failure, 
oxygen therapy and treatment of symptoms constitute the mainstay of 
therapy. Severe acute respiratory distress, pneumonia, renal failure and 
death are associated with severe forms of the infection. It is challenging 
to compute the number of asymptomatic individuals infected with 
COVID-19 [10]. 
2. Biology of coronaviruses 
Coronaviruses are a large family of viruses that vary greatly in 
genotypic and phenotypic characteristics [1,15,16]. This family of vi-
ruses target the human respiratory tract [1]. Coronaviruses are classified 
into four classes: alphacoronaviruses, betacoronaviruses, gammacor-
onviruses, and deltacoronaviruses. SARS-CoV, SARS-CoV-2, and 
MERS-CoV are classified in the betacoronavirus [17]. These viruses 
belong to the Coronaviridae family and Orthocoronavirinae subfamily, 
which are enveloped viruses containing single-stranded positive-sense 
RNA (Table 1) [18]. 
The viral genome is about 27–32 kb that encode structural proteins, 
including membrane (M), envelope (E), nucleocapsid (N), and spike (S) 
proteins, and nonstructural proteins (NSPs), which play a major role in 
viral entry and replication in the host cell of birds, mammals, and 
humans [15,16]. CoVs are the largest RNA viruses have been identified 
in various hosts such as avian, bats, mice, dogs, cats, camels, and masked 
palm civets. CoVs transmission from animals to humans has made them 
a zoonotic virus [19]. 
Similar to SARS-CoV and MERS-CoV, the novel virus attacks to lower 
respiratory tract and causes viral pneumonia. However, gastrointestinal 
tract, heart, kidneys, liver, and central nervous system may also be 
affected, and organ failure may occur [5,20]. The new coronavirus 
primarily targets the respiratory system and systemically spreads to the 
heart, liver, and kidneys through the lungs [21]. This is due to the high 
expression of the angiotensin-converting enzyme 2 (ACE2) receptor in 
lungs and bronchial branches cells in the respiratory tract. Other systems 
in the body, including the cardiovascular system (CVS), central nervous 
system (CNS), gastrointestinal tract (GIT), female and male reproductive 
systems, can be infected due to the presence of virus-targeted receptors 
in their cells [22–24]. Endothelial cells and CVS have a high expression 
of ACE2, which is effective in regulating blood pressure and myocardial 
contractility. By binding SARS-CoV-2 to the ACE2 as the surface receptor 
of these cells, a series of downstream ACE2 signals are activated. For 
example, the RAS-ERK and AP-1 pathways are activated, which ulti-
mately activate the CC motif chemokine ligand 2 (CCL2) that is a 
pro-fibrosis factor and may cause heart inflammation and heart fibrosis 
[23,25]. The CNS may be infected by four different ways [26], including:  
1. Direct infection can occur through the blood circulatory and neural 
pathways. SARS-CoV-2 causes infection by increasing the perme-
ability of the blood-brain barrier (BBB) through the cytokine storm 
mechanism. In the latter case, the sensory nerve ending is the pri-
mary target for viral infection, which may lead to anterograde or 
delayed axonal transmission by motor kinesin and dyneins [23,26, 
27]. 
2. Hypoxia damage: As a result of viral infection in lung tissue, disor-
ders of alveolar gas exchange originate a lack of oxygen in the CNS 
and elevate anaerobic metabolism in the mitochondria of brain cells. 
The lack of oxygen eventually leads to high blood pressure (head-
ache), sleepiness (drowsiness), and swelling of the olfactory bulbs 
(loss of taste), which can cause severe CNS damage [23,26,27]. 
3. During the COVID-19 infection, the brain’s immune cells are acti-
vated, resulting in a severe cytokine storm, leading to severe brain 
damage [23,26].  
4. Binding of SARS-CoV-2 to ACE2 of capillary endothelium may 
damage the BBB and facilitate viral entry by invading the vascular 
system [23,27]. Consequently, SARS-CoV-2 reaches CNS through 
destroying the BBB and attacking to the endothelial layer [27]. 
SARS-CoV-2 can use an alternative route through the olfactory bulb 
instead of the common blood circulation system. In this pathway, the 
Table 1 
Classification of coronaviruses.  
Order Nidovirales 
Family Arteriviridae Roniviridae Mesoniviridae Coronaviridae 
Subfamily _ _ _ Coronavirinae Torovirinae 
Genus Arterivirus Okarivirus α-Mesonivirus Alphacoronavirus Bafinivirus 
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virus may enter the CNS via the cribriform plate of the olfactory bulb and 
pass the neurons along with blood vessels and epithelial cells [27]. 
Tissues with high expression of ACE2 and TMPRSS2 genes may be more 
vulnerable to COVID-19 infection, especially those tissues and organs 
with higher association between ACE2 and TMPRSS2 genes expression 
[28]. ACE2 is highly expressed in the reproductive organs, especially in 
the uterus, placenta, and fetal interface of pregnant women. So apart 
from the transmission through droplets and contact, the possibility of 
mother-to-child and sexual transmission also exists. Angiotensin II (Ang 
II), Ang-(1− 7), and ACE2 regulate follicle development and ovulation, 
modulate luteal angiogenesis and degeneration, and also influence the 
regular changes in endometrial tissue and embryo development. Taking 
these functions into account, SARS-CoV-2 may disturb the female 
reproductive functions through regulating ACE2 [29]. It has been re-
ported that COVID-19 is usually accompanied by high levels of inter-
leukin (IL)− 6, IL-8, tumor necrosis factor-α (TNF-α), and other 
cytokines, which trigger a procoagulant state that is unfavorable to the 
development of blastocyst or fetus in a normal human uterus. An 
epidemiological study demonstrated that coronaviruses could have 
adverse effects on fetuses and infants, including intrauterine growth 
restriction, preterm delivery, spontaneous abortion, and even death 
[14]. 
During the COVID-19 pandemic, the binding of SARS-CoV-2 to ACE2 
receptor counteracts preeclampsia in the reproductive system of preg-
nant women and increases mortality rate [23]. With this consideration, 
the regulatory effects of COVID-19 on ACE2 may disturb the female 
reproductive functions and induce infertility, menstrual disorder and 
fetal distress [29]. In the human reproductive system, especially in the 
germ and somatic cells of testicles, the expression of ACE2 is high. In 
addition, transmembrane protease serine 2 (TMPRSS2), that assists in 
the virus-cell fusion process needs to be present. However, the expres-
sion of TMPRSS2 is rare in testicular tissue (15). Therefore, there are 
doubts about whether the testicle is a vulnerable organ in COVID-19 [22, 
30]. 
Bats host the largest number of coronaviruses and seem to be im-
mune to coronavirus diseases [31]. Bats are resistant to RNA viruses 
based on the evolution of their multifaceted antiviral immune system. 
The evolution of the immune system has created unique antiviral re-
sponses in this mammal. This evolution occurs at the gene and protein 
levels in bats. The evolution of flight in bats and concomitant with in-
fectious viruses has shaped its distinct immune response [32,33]. 
After the emergence of COVID-19, the complete SARS-CoV-2 genome 
was registered on the National Center for Biotechnology Information 
(NCBI) database (GenBank: MN908947.3). In addition, information 
about the structure and glycosylation pattern of the proteins and host 
cell communication was provided by Wu et al. in 2020 [34]. 
3. Structure of SARS-CoV-2 
Similar to most other betacoronaviruses, their genome is made up of 
approximately 30,000 nucleotides. Four structural proteins, including 
N, M, S, and E proteins, and several NSPs are encoded by the genome 
(Fig. 1) [35,36]. 
The genetic material of the virus is enclosed in a lipid envelope. The 
capsid is a protein coat, containing nuclear capsid or N proteins. N 
proteins bind to viral single positive-strand RNA and play an important 
role in virus replication and transcription. These proteins help the virus 
take over host cells. M protein with the highest amount at the cell sur-
face of the virus affects the viral assembly. Protein E is also a small 
membrane protein that is involved in the viral assembly and the inter-
action of virus with the host cell through the permeability of the host cell 
membrane. Hemagglutinin-esterase (HE) dimer, which is located on the 
surface of the virus, in spite of its negligible importance in virus repli-
cation, is considered essential for infecting host cell [36]. The viral 
membrane is studied with S glycoprotein that gives coronaviruses a 
crown-like appearance. The coronavirus name is a derivative from the 
Latin corona, describing its characteristic structure of surface projections 
on the viral envelope giving it an appearance similar to a crown [9]. This 
glycosylated protein is the prime viral interacting protein with host cell 
targets such as angiotensin-converting enzyme 2 (ACE2), CD26, Ezrin, 
cyclophilins, and other cell adhesion factors. In addition, S protein is 
important for cell adhesion and viral virulence [37–39]. 
4. Mechanism of COVID-19 infection 
In both SARS-CoV and SARS-CoV-2, the S protein binds to ACE2 as its 
receptor on host cells [40]. Cryo-EM structure analysis has revealed that 
the binding affinity of S protein to ACE2 in SARS-CoV-2 is about 10–20 
times higher than that of the S protein from SARS-CoV [41]. Since the 
process of viral infection begins with the interaction of S protein and 
ACE2 on the host cell surface, this step is of particular importance. In 
studies with the presence of serine protease, the invasive process of the 
virus is facilitated by the S protein [42,43]. During infection, NSPs 
including RNA-dependent RNA polymerase (RdRp), 3C-like protease 
(3CLpro), and papain-like protease (PLpro) are encoded by the viral 
genome [42,43]. Once the virus enters the host cell, the viral genome 
Fig. 1. Schematic structure of SARS-CoV-2. The SARS-CoV-2 virus contains different structural and non-structural proteins.  
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(single-stranded positive RNA) is released and consequently the viral 
proteins are produced by employing the host cell’s protein translational 
system. The viral proteinases, including 3CLpro and PLpro cleave pro-
teins to their effector forms [42]. PLpro acts as a de-ubiquitinating 
enzyme or deubiquitinase and may ubiquitinate certain host cell pro-
teins, including interferon factor 3 and nuclear factor kappa B (NF-κB), 
resulting in immune suppression [42,44]. To make more viral genomic 
RNA, RdRp enzyme synthesizes a full-length negative-strand RNA tem-
plate to be used in the next steps (Fig. 2) [41]. 
The viral S protein binds to the ACE2 receptor of the host cell. 
Transmembrane serine protease2 (TMPRSS2) cleaves viral S glycopro-
tein to facilitate viral activation. As the virus enters the cell by endo-
cytosis, a proteolytic cleft is produced in the viral envelope, causing the 
RNA genome to be released in the cytoplasm. The RNA is translated by 
host machinery to produce the replicase and structural proteins. Host 
and SARS-CoV-2 proteases cleave the replicase into NSPs such as RNA- 
dependent RNA polymerase (RdRp). RdRp mediates RNA replication 
and amplification for SARS-CoV-2. Viral polypeptides and NSPs are 
translated from the viral genome using RNA-dependent RNA polymerase 
(RdRp). The viral genome is also translated into structural proteins (S, 
M, and N) to assemble a new virus. The translation of M, E, and S pro-
teins occurs in the endoplasmic reticulum (ER) resulting in their accu-
mulation in the ER-Golgi compartment (ERGIC) as well as cis-Golgi 
apparatus. N protein is produced in the cytoplasm, which is combined 
with the newly generated genome to form ribonucleoproteins (RNPs). As 
the new virus is assembled (mature virion), the virus is fused into the 
plasma membrane using the vesicles in the intermediate ERGIC, and the 
virus is released eventually. The severe outcome in COVID-19 and 
immunopathology of SARS-CoV-2 can be associated to monocyte- 
macrophage cells. 
5. Antiviral therapy for COVID-19 
COVID-19 has become a global pandemic and has spread at an 
exponential rate and on the other hand, there are still no effective drugs 
to treat this viral infection even though some non-specific therapeutic 
options are exist [10]. 
All potential drugs with antiviral efficacy on SARS-CoV-2 have been 
listed in Table 2. 
5.1. Chloroquine and hydroxychloroquine 
Chloroquine (CQ) and Hydroxychloroquine (HCQ) have a long- 
standing history in the prevention and treatment of malaria and the 
treatment of chronic inflammatory diseases, including systemic lupus 
erythematosus (SLE) and rheumatoid arthritis (RA) [64]. HCQ is derived 
from CQ and both compounds have been used for treating COVID-19 
disease [65]. 
Compared with QC, the derivative HQC has fewer side effects, drug- 
drug interactions, and toxicity [66]. Studies on Vero E6 cells have shown 
that the antimalarial drug CQ, between its half-maximal effective con-
centration (EC50) of 1.1 μM and its 90% maximal effective concentra-
tions (EC90) of 6.9 μM, is effective against COVID-19 [67]. HCQ is more 
effective (EC50 5.47 μM) [65]. The mechanism of action of the two 
drugs on viral cells is to inhibit glycosylation of host receptors, proteo-
lytic processing, and endosomal acidification. CQ and HCQ, also have 
Fig. 2. Schematic representation of the entrance and propagation of SARS-CoV-2 in host cells.  
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immunomodulatory effects through attenuation of cytokine production 
and inhibition of autophagy and lysosomal activity in host cells [68,69]. 
In addition, nucleic acid replication is inhibited by these drugs. 
The use of CQ in high doses or along with macrolides may cause side 
effects, including cardiac toxicity [70]. Meanwhile, bundle-branch 
block, incomplete or complete atrioventricular block, Quiet Torpedo 
(QT) prolongation and subsequent “torsade de pointes” (a specific 
electrocardiographic form of polymorphic ventricular tachycardia) and 
cardiomyopathy (hypertrophy and congestive heart failure) can be other 
side effects, which are caused by CQ/HCQ in patients [71]. Patients with 
COVID-19 who have previous underlying diseases, including diabetes, 
obesity, and cardiovascular disease, are more at risk of side effects by 
prescription of CQ/HCQ [71]. Based on the provided information on the 
CQ and HCQ, they were no longer supported further for treating 
COVID-19. However, given the increasing demand for these two drugs 
and the number of people who use CQ and HCQ, they must necessarily 
consider the clinical and social effects of long-term hearing effects [72]. 
To prove the efficacy and safety of CQ and HCQ for treating COVID-19, 
near twenty-three clinical trials have been conducted in China [73–75]. 
Despite the side effects of CQ, the drug indicated to be effective in 
treating and curing 100 patients with COVID-19 [74]. These observa-
tions showed that this drug should be prescribed at a dose of 500 mg 
twice per day for 10 days to patients with mild, moderate and severe 
COVID-19, who were not contraindicated in CQ. 
Several inconsistent treatment studies have shown that cardiac side 
effects may be increased with HCQ and azithromycin [76,77]. On April 
24, 2020, the US Food and Drug Administration (FDA) issued a state-
ment on the treatment of CQ and HCQ for treating COVID-19 out of 
hospital or clinical trials: “HCQ and CQ can cause abnormal heart 
rhythms such as prolonged QT and ventricular tachycardia." The FDA 
noted that QT prolongation is more common in people receiving azi-
thromycin and those with underlying heart or kidney diseases [78]. 
A recent controversial study by Prodromos et al., on the possible side 
effects of HCQ in patients with COVID-19 revealed that not only HCQ 
azithromycin is not cardiotoxic and does not cause cardiac arrhythmia 
and mortality, but also protect the heart with reducing cholesterol, 
thrombosis, and arrhythmia in the treated patients [79]. 
Clinical studies of CQ and HCQ in COVID-19 infection reported 
conflicting results. Moderate certainty evidence suggests that HCQ, with 
or without azithromycin, lacks efficacy in reducing short-term mortality 
in patients hospitalized with COVID-19 or risk of hospitalization in 
outpatients with COVID-19 [80]. 
Despite of promising in vitro results, the last update of international 
randomized controlled trials (RCTs) for COVID-19 treatments launched 
by WHO concluded that HCQ had little or no effect on overall mortality, 
initiation of ventilation, and duration of hospital stay in hospitalized 
patients, whereas potential effectiveness at the early stage of the dis-
eases should be confirmed [66]. In summary, although CQ or HCQ have 
been promoted as potential anti-COVID-19 drugs, the evidence for their 
clinical effectiveness is insufficient in COVID-19. The FDA has revoked 
emergency use authorization (EUA) for CQ and HCQ as the known risks 
outweighs potential benefits with their use. Since CQ and its derivatives 
affect a multitude of mechanisms in the lung, further studies are 
necessary to identify structurally similar drugs that are safe in viral 
associated diseases including COVID-19 [81]. 
5.2. Azithromycin 
Although the preponderance of evidence indicates that there is no 
benefit of HCQ for treating COVID-19, fewer studies have evaluated 
azithromycin along with HCQ, a broad-spectrum antibiotic with anti- 
inflammatory properties [82]. Azithromycin is an antibacterial com-
pound, which exhibits significant anti-inflammatory properties against 
bacterial lipopolysaccharide (LPS)-induced inflammation in pneumonia 
Table 2 
Drugs with antiviral efficacy on SARS-CoV-2.  
No. Drug The main objective The main use of drug References  
1 Chloroquine and 
Hydroxychloroquine 
Inhibit glycosylation of host receptors, proteolytic processing, and 
endosomal acidification 
Malaria and chronic inflammatory diseases including 
systemic lupus erythematosus (sle) and rheumatoid 
arthritis (ra) 
[45]  
2 Azithromycin Broad-spectrum antibiotic with anti-inflammatory properties a Variety of community-acquired respiratory tract, skin and 
soft tissue, and sexually transmitted disease infections. 
[46]  
3 Lopinavir/Ritonavir Acts against the viral 3CL protease. HIV, SARS, MERS [47]  
4 Ribavirin Guanine analog SARS, MERS [48] 
Inhibition RNA-dependent RNA polymerase for replicating viral 
genome  
5 Tocilizumab Specifically binds to soluble and membrane-bound IL-6 receptors 
(IL-6R), thus blocking IL-6 signalling and its mediated 
inflammatory response 
Rheumatic diseases, such as rheumatoid arthritis [49]  
6 Baricitinib Jak kinas inhibitor SARS [50]  
7 Remdesivir Inhibition RNA-dependent RNA polymerase Hepatitis B and C, Ebola, and Marburg virus, human 
immunodeficiency virus (HIV) 
[51]  
8 Favipiravir A purine nucleic acid analogue that inhibits RdRp Arenavirus, Bunyavirus, Flavivirus, and Filoviruses 
causing hemorrhagic fever and Ebola 
[52]  
9 Abidol Inhibiting the fusion of viral cells into the target cell membrane 
(inhibition S-protein- ACE2), and preventing the virus from 
entering the target cell 
Influenza, SARS [53]  
10 Ruxolitinib Janus kinase inhibitor Intermediate or high-risk myelofibrosis [54]  
11 Teicoplanin A lipoglycopeptide used for treatment of gram-positive bacterial 
infections, especially in staphylococcal infections 
MERS-CoV and SARS-CoV, ebola, influenza, and hepatitis 
C viruses as well as flavivirus and HIV 
[55,56]  
12 Ivermectin Boosts the immune system by increasing the production of IL-1 
and other cytokines, as well as activation of superoxide anion 
production and augmentation of lymphocyte response to 
mitogens. 
An antifungal drug, RNA viruses such as respiratory 
syncytial virus (RSV), dengue, influenza, rabies, and Zika 
viruses 
[57–59]  
13 Corticosteroid Anti-inflammatory and immunosuppressive properties Primary and secondary hemophagocytic 
lymphohistiocytosis (HLH) syndrome and inflammation 
associated with acute respiratory distress syndrome 
(ARDS) 
[60,61]  
14 Doxycycline Inhibitory action on metalloproteases and modulating effects of 
pro-inflammatory cytokines IL-6, IL-8, and TNF-α 
Antibiotic effects (bacteriostatic action by inhibition of 
bacterial protein synthesis, anti-inflammatory effects, anti- 
RNA viruses and ARDS 
[62,63]  
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[83,84]. According to a study by Stellari et al., pretreatment of patients 
with COVID-19 with azithromycin can significantly decrease 
LPS-induced lung bioluminescence and airway cell infiltration, reduce 
the concentration of proinflammatory cytokines in bronchoalveolar 
lavage and inhibit NF-κB nuclear translocation [84]. Studies on the 
antiviral activity of azithromycin have also been conducted on RNA 
viruses such as Zika virus, rhinovirus and SARS-CoV-2. In the case of 
COVID-19, this antibiotic had no direct effect on patients’ recovery 
process, while some scientists have suggested that the antibacterial 
properties of azithromycin have been clinically effective in the experi-
mental treatment of severe acute respiratory syndrome, which occurs in 
patients with COVID-19 [82]. However, not all current treatment 
guidelines agree on the use of azithromycin in improving 
community-acquired pneumonia [82,85]. Nevertheless, there are some 
reports that hospitals have begun including azithromycin along with CQ 
or HCQ to treat patients with COVID-19 [86]. 
Based on duality, it is required that the clinical pharmacology and 
characteristics of azithromycin could be considered in clinical trials 
alone or combined with other agents to ensure its efficacy for treating 
patients with COVID-19 and to increase the probability of achievement 
to a definitive treatment protocol [86]. 
In studies conducted on patients with COVID-19, preclinical data 
showed that consumption of 600-mg HCQ per day was effective in 70% 
of patients (n = 20). The use of azithromycin also increased the thera-
peutic effect of HCQ [87]. Azithromycin, as a weak base has antimi-
crobial properties and is commonly used for treating patients with 
chronic pulmonary disorders [60]. 
5.3. Lopinavir/ritonavir 
Lopinavir and ritonavir (LPV/r or Kaletra) were approved by FDA in 
2000 for treating human immunodeficiency virus-1 (HIV-1) infection 
[88]. LPV acts against the viral 3CL protease [89,90]. Two serum con-
centrations of LPV including 9.6 µg/mL (peak level) and 5.5 µg/mL 
(trough level) were effective in the inhibition of SARS-CoV [91]. 
Lopinavir-1 is an HIV protease inhibitor and is usually administered 
with another protease inhibitor (ritonavir). After the entrance of the 
viral particles into the cells, LPV blocks the post-entry step in the 
MERS-CoV and inhibits its replication cycle [92]. 
Ritonavir increases the serum concentration of LPV by inhibiting 
cytochrome P450 [93]. In addition, by increasing the serum concen-
tration of LPV, ritonavir inhibits the CYP3A-mediated metabolism of 
LPV. Combination in LPV/r showed that the antiviral activity is still 
similar to that of LPV alone, suggesting that the effect is largely driven 
by LPV [90,94]. 
In vitro studies have shown that lopinavir has antiviral activity in 
SARS-CoV and MERS-CoV [92,93,95], so, the patients with SARS-CoV 
were treated with LPV/r. The outputs showed favorable clinical results 
compared with the control group who has not received LPV/r. Although 
XT Ye et al. reported that Kaletra or LPV/r may be more effective for 
treating COVID-19 infections [96], more studies are needed on a larger 
scale to clarify its effectiveness. 
For further evaluation of LPV within the epidemiological and clinical 
aspects, the LPV was prescribed to ten patients with COVID-19. Of 
course, the drug was discontinued in three patients due to side effects. 
After administration of Kaletra, the levels of potassium, albumin and 
lymphocytes were increased. In addition, the eosinophil count returned 
to its normal range. Meanwhile, following the administration of lopi-
navir, an increase in the eosinophil count may be a sign of improvement 
in patients with COVID-19 [97]. 
5.4. Ribavirin 
Due to the availability and low cost, ribavirin is used as a drug to 
treat coronavirus infections [98]. Ribavirin is an analog of guanine and 
can inhibit viral RNA-dependent RNA polymerase. Its approved activity 
against other coronaviruses makes it a potential candidate for COVID-19 
treatment. 
The challenges related to the administration of ribavirin for treating 
SARS-CoV and MERS-CoV infections were studied in 2003 and 2013, 
respectively. Those findings led to its assessment as controversial for 
treating COVID-19 infections [98]. To treat SARS-CoV using ribavirin, 
an in vitro study revealed that a combination therapy with high dose 
concentrations of ribavirin (eg, 1.2–2.4 g orally every 8 h) is required to 
inhibit viral replication [99]. Among 30 clinical trials on ribavirin, 26 
studies showed ineffectiveness of the treatment on SARS-CoV infection 
and in 4 studies some side effects including hematologic and liver 
toxicity was observed [99]. 
For treating MERS with ribavirin and in the combination with in-
terferons, no discernible effect on clinical outcomes or viral clearance 
was demonstrated [100,101]. Among the possible studies related to 
COVID-19 treatment procedures, drug combination approach using 
ribavirin is used extensively. In addition and according to the available 
evidence, the in vitro antiviral activity of ribavirin against SARS-CoV-2 
strain WIV04 has been demonstrated [67,98]. 
The drug potential in low doses is well managed based on treatment 
synergies [67,98]. Also, the efficacy and safety of combined interferon 
beta-1b (IFN-β1B), Kaletra, and ribavirin for treating patients with 
COVID-19 was assessed [102]. The study was conducted in phase II of 
clinical trials on adult patients with COVID-19 in six Hong Kong hos-
pitals. In addition, the project was a multicenter, prospective, 
open-label, and randomized study. In this study, the combination of 
lopinavir, ritonavir, ribavirin, and interferon-β1B (IFN-β1B) was pre-
scribed. The primary endpoint was the time to provide a nasopharyngeal 
swab negative for RT-PCR. 
Compared to other COVID-19 treatment strategies, triple-drug 
administration has been effective in shortening the hospitalization 
period of acute and mild to moderate patients with COVID-19, reduction 
of symptoms, and duration of viral shedding. Meanwhile, the presence 
of IFN-β1B as a backbone for double antiviral treatment was warranted 
[102]. 
5.5. Tocilizumab 
Tocilizumab (TCZ) or Actemra is a monoclonal antibody which is 
widely used in treatment of rheumatic diseases such as rheumatoid 
arthritis. TCZ is one of the drugs approved in the United States on August 
30, 2017, for severe life-threatening cytokine release syndrome caused 
by chimeric antigen receptor (CAR) T-cell Immunotherapy [103]. 
Interleukin-6 (IL-6) is highly expressed in patients with SARS and MERS 
as well as COVID-19 [104–106]. TCZ can be prescribed to patients with 
COVID-19 who are in the risk of cytokine storm. TCZ as a recombinant 
human monoclonal antibody binds to soluble and membrane-bound IL-6 
receptors (IL-6R), and stops IL-6 signals and production of intermediate 
inflammatory molecules [107]. TCZ is considered a pharmaceutical 
option for treating patients with COVID-19, however, during the treat-
ment procedures, clinicians should evaluate the safety and efficacy of 
TCZ. 
During the administration of TCZ in patients with COVID-19, 
screening and monitoring parameters, especially latent tuberculosis 
test (TB) should be performed by IFN-g release assay (IGRA) before and 
during the treatment. Studies on phase III trials associated with TCZ 
revealed that it will be crucial in the reduction of severe respiratory 
symptoms in patients with COVID-19 [108]. 
During the treatment of patients with COVID-19 through TCZ ther-
apy, some laboratory parameters including C-reactive protein (CRP) and 
IL-6 concentrations should be assessed before and after TCZ therapy. In 
addition, TCZ was used along with methylprednisolone in some patients 
with COVID-19. The studies have shown that the level of IL-6 decreased 
in patients after taking TCZ, while the level of IL-6 increased signifi-
cantly in patients who were not treated with TCZ. TCZ appears to be an 
effective treatment option in patients with COVID-19 at high risk of 
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cytokine storm. Meanwhile, a repeated dose determination of TCZ is 
recommended for patients with high IL-6 [107]. 
5.6. Baricitinib 
Baricitinib is one of the leading pharmaceuticals recommended for 
treating pneumonia associated with COVID-19 [68,109]. This com-
pound is known as a safe drug with high affinity to infected cells [68]. 
Regarding the SARS virus, the most important receptor for glycoprotein 
S binding was the angiotensin-converting enzyme 2 (ACE2) in the 
human cells. In the SARS-CoV-2 and due to the structural similarity of 
glycoprotein S with that found in SARS virus, ACE2 plays the major 
receptor for viral entrance. This viral receptor is widely present in kid-
ney cells, heart, blood vessels and especially in lung AT2 alveolar 
epithelial cells [110]. These cells are prone to viral infections such as 
SARS, so, they are effective in the reproduction and transmission of viral 
particles through endocytosis [68,111]. 
SARS-CoV-2 invades and enters the cell through endocytosis. Two 
important promoter factors in endocytosis are two kinases, including 
AP-2 associated protein kinase 1 (AAK1) and cyclin G-associated kinase 
(GAK) [112,113]. Kinase inhibitors such as baricitinib prevent the 
entrance of viral particles to host cells and assembly of the viral parti-
cles, thus reduce viral infection [114]. To achieve an inhibitory dose in 
plasma, it is sufficient to prescribe 2–4 mg/day of baricitinib [68]. 
Meanwhile, due to the risks posed by bacitracin in patients with 
COVID-19, it will not be an effective drug for treating COVID-19. Some 
studies have demonstrated that baricitinib should not be used in patients 
with neutrophil and lymphocyte counts less than 1 × 109 cells/L and 
0.5 × 109 cells/L, respectively [115,116]. The progression of infection 
in patients with COVID-19 can be affected by lymphocytopenia. Bar-
icitinib causes anemia in several patients. In addition, the incidence of 
anemia can occur in non-survivor patients with COVID-19 with 26% 
probability. Hence, the usage of baricitinib in COVID-19 may further 
reduce the number of patients [117]. 
According to the statistics, the level of creatine kinase (normal: 
< 175 U/L) in patients who took bacitracin exceeded the permissible 
level. Alternatively, elevated CK levels pose a risk for initiating bar-
icitinib therapy [117]. There are limited data on the potential effects of 
bacitracin in the elderly aged over 75 years. In studies conducted by 
Zhou et al., mortality was higher in elderly patients [115] . 
Co-infection, as well as the risk of reactivation of latent infections, is 
an important risk in the management of COVID-19 [118]. Studies have 
shown that baricitinib reactivates viruses, including the varicella zoster, 
herpes simplex, and Epstein-Barr virus strains. There is also a risk of 
reactivation of latent infections. Zhou et al. proved that approximately 
50% of the patients with COVID-19, also experienced a secondary 
infection [115]. 
5.7. Remdesivir 
Remdesivir, formally known as GS-5734 with similar structure to 
tenofovir alafenamide, is a nucleotide analog of adenosine 5-monophos-
phate [119]. This molecule has a broad-spectrum antiviral activity 
against hepatitis B and C, Ebola, and Marburg viruses [120], as well as 
human immunodeficiency virus (HIV) [121]. This agent was initially 
approved during the screening process for its antiviral activity against 
coronaviridae and flaviviridae. With the advent of the Ebola virus and 
further research on the effective drug, researchers have found that 
remdesivir can be an effective compound for treatingthe Ebola virus 
infection due to its low EC50 and host polymerase selectivity against the 
Ebola virus [122]. Meanwhile, in vitro and in vivo studies on remdesivir 
has shown an anti-viral inhibition activity against SARS-CoV-2 [123]. 
The mechanism of action of remdesivir is interference with RdRp ac-
tivity through the inhibition of the virus replication [123]. In the pres-
ence of this pharmaceutical molecule, prolongation of the viral RNA is 
prevented [120]. The first case of COVID-19 in Washington, USA, was 
compassionately treated with intravenous (IV) administration of 
remdesivir to stop the progression of pneumonia on day 7 of hospitali-
zation [124]. Studies have shown that remdesivir is a potential therapy 
for COVID-19 due to its in vitro potent and broad-spectrum, activity 
against several SARS-CoV-2 strains with EC50 and EC90 values of 
0.77 μM and 1.76 μM, respectively [125,126]. 
Despite the side effects, remdesivir has yielded acceptable results for 
treating patients with COVID-19. However, further studies are needed to 
prescribe remdesivir with minimal side effects on patients with COVID- 
19 [123]. An in vivo study in mice with MERS-CoV infection showed that 
remdesivir is an effective drug in the prevention of pulmonary hemor-
rhage and is capable of reducing the viral titer [90]. Albeit, it should not 
be neglected that remdesivir was not originally designed to target 
COVID-19 [120]. 
To evaluate the safety and pharmacokinetics of remdesivir, the drug 
was evaluated in single- and multiple-doses associated to phase I clinical 
trial. The results revealed that IV infusion of 3–225 mg remedsivir posed 
no adverse risk to the kidneys or liver [127]. Remdesivir was approved 
by FDA on May 01, by Japan on May 07, 2020, and subsequently by 
various European countries and Canada [128]. Further studies are 
needed on its safe and efficient prescription in children and pregnant 
women. 
Since April 19, 2020, several studies have been conducted in the 
United States to investigate the effect of remdesivir on the treatment of 
patients with COVID-19. In a recent study by Grein et al., the efficacy of 
remdesivir was evaluated in 61 patients with COVID-19. Several mod-
erate side effects such as renal impairment, rash, diarrhea, increment of 
hepatic enzymes, and hypotension have been reported in 32 patients. 
Also, 12 patients experienced severe side effects, including septic shock, 
multiple-organ-dysfunction syndrome, hypotension, and acute kidney 
injury. In addition, the treatment was stopped in four patients due to 
deteriorating preexisting renal failure and multiple organ failure as well 
as increased transaminases in two patients, including one patient with a 
maculopapular rash [129]. 
5.8. Favipiravir 
Favipiravir is a purine nucleic acid analog and a pyrazine carbox-
amide derivative (6-fluoro-3-hydroxy-2-pyrazine carboxamide). Previ-
ously, favipiravir was known as T-705-RTP that is related to ribosylated 
and phosphorylated prodrug, which intracellularly forms the active 
metabolite favipiravir-ribofuranosyl-5’-triphosphate (Favipiravir-RTP). 
In Japan, favipiravir is prescribed as a broad-spectrum antiviral drug to 
treat influenza. A study showed that the half-maximal inhibitory con-
centration (IC50) of favipiravir can inhibit RdRp from the influenza 
virus, whereas human DNA polymerases α, β, and γ subunits are not 
inhibited by favipiravir at up to 100 µg/mL [130]. 
Favipiravir is effective in the inhibition of RNA viruses, including 
arenavirus, bunyavirus, flavivirus, and filoviruses causing hemorrhagic 
fever [131]. With the emergence of Ebola virus, favipiravir was used to 
treat patients, which showed significant effects on the treatment of the 
disease [132]. Some studies have been done on the treatment of 
COVID-19 with favipiravir. In one study, Wang et al. demonstrated that 
favipiravir requires a high therapeutic concentration compared with 
remdesivir (EC50 = 61.88 μM) [67]. However, in previous in vivo 
studies in mice infected with the Ebola virus, favipiravir showed a 
considerable efficacy in the reduction of viral response and mortality 
[133,134]. 
In a non-randomized trial, 80 patients with COVID-19 were treated 
with favipiravir. In this group of patients, the duration of treatment was 
shorter than in the control group treated with LPV/r [135]. 
5.9. Abidol-umifenovir 
One of the approved antiviral agents in China and Russia is Abidol. 
This compound works against a large number of enveloped and non- 
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enveloped viruses such as influenza, SARS, and Lassa viruses [136,137]. 
Abidol exerts its antiviral properties by inhibiting the fusion of viral 
particles into the target cell membrane and preventing the virus from 
entering the target cell [137]. There have been few reports of this drug’s 
effect on patients with COVID-19. 
A limited number of COVID-19 studies report data about patients 
receiving LPV/r and arbidol. It is challenging to identify whether pa-
tients have recovered naturally or the recovery process is associated 
with medications. Studies by Zhen Zhu et al. have shown that arbidol 
monotherapy is more effective than LPV/r for treating patients with 
COVID-19 [136]. Contrary to that, Deng’s reported that the efficacy of 
LPV/r alone is higher than the combination of arbidol and LPV/r for 
treating patients with COVID-19 [138]. 
5.10. Ruxolitinib 
Ruxolitinib is commonly used for treating patients with intermediate 
or high-risk myelofibrosis [21]. Ruxolitinib as a Janus kinase (JAK) in-
hibitor was prescribed in a phase III clinical trial of patients with 
COVID-19 associated with cytokine storm. However, due to the broad 
immunosuppressive effects of JAK kinase inhibitors, the US National 
Institute of Health (NIH) did not recommend the application of rux-
olitinib for control of cytokine storm in patients with COVID-19 [58]. 
5.11. Teicoplanin 
Teicoplanin is a lipoglycopeptide used for treating gram-positive 
bacterial infections, especially in staphylococcal infections. Some 
studies have shown that this protein can show anti-viral activity against 
coronaviruses such as MERS-CoV and SARS-CoV. In addition, several 
studies have been conducted on the effect of teicoplanin on Ebola, 
influenza, and hepatitis C viruses as well as flavivirus and HIV [55,56]. 
According to a study by Zhou et al. on the coronaviruses, teicoplanin 
inhibits the low pH cleavage of the viral spike protein in the early step of 
viral life cycle. The mechanism of action is the inhibition of cathepsin L 
in the late endosomes and consequently prevents the release of genomic 
viral RNA and replication cycle. An in vitro study showed that 1.66 µM of 
teicoplanin is required to inhibit the replication of 50% of viruses 
(IC50). Comparing the in vitro and in vivo conditions revealed that a 
higher blood concentration (8.78 µM) of teicoplanin is needed to reduce 
blood pH in human [58,139]. Based on the similarity between the in-
fectious process of the SARS-Cov-2 and other coronavirus strains, tei-
coplanin has been used as a potential therapeutic agent [139]. 
5.12. Ivermectin 
Ivermectin is an antifungal drug, which is prescribed as a treatment 
for cutaneous larva migrans [57]. Ivermectin boosts the immune system 
by increasing the production of IL-1 and other cytokines, as well as 
activation of superoxide anion production and augmentation of 
lymphocyte response to mitogens [58]. Ivermectin has been reported to 
be effective in treating infections caused by RNA viruses such as respi-
ratory syncytial virus, dengue, influenza, rabies, and Zika viruses [59, 
140]. 
Ivermectin inhibits the replication of human immunodeficiency virus 
(HIV) by inhibiting the interaction of the HIV-1 integrase and α/β1 
heterodimer of importin. Notably, importin is responsible for the nu-
clear import of integrase [58]. 
In an in vitro study by Caly et al., ivermectin was used as a potential 
replication inhibitor of SARS-CoV-2. They showed that the addition of 
5 μM ivermectin to virus-infected Vero/hSLAM cells was capable of 
reducing SARS-CoV-2 RNA level about 5000-fold, compared to controls 
within 48 h [140]. 
According to another study by Chaccour et al., the concomitant 
prescription of HCQ and ivermectin could be effective for treating 
COVID-19. This could be related to the mechanism of action of both 
drugs. HCQ prevents the entrance of viral particles to host cells in the 
first phase of viral attack, while ivermectin prevents the genome repli-
cation of the virus [57]. In addition and within this context, ivermectin 
appears to be an immunosuppressive drug with no adverse drug in-
teractions. However, no in vitro or in vivo studies have been conducted in 
this regard. 
In a study by Alam et al., ivermectin along with doxycycline was 
applied for treating patients with COVID-19. In this research, 100 pa-
tients (64 males and 36 females) were enrolled with a predefined in-
clusion and exclusion criteria. During the medications, all patients were 
tested twice (4 and 18 days of starting the medication). Based on the 
results obtained from RT-PCR and other screening methods, the com-
bination of ivermectin and doxycycline provided better viral clearance 
in patients with COVID-19 with mild and moderate symptoms [141]. 
In another study by Rahman et al., a comparison was done on the 
viral clearance between ivermectin with doxycycline and HCQ with 
azithromycin in patients with COVID-19. One group of the patients 
received ivermectin with doxycycline and another group received HCQ 
with azithromycin. Based on the results obtained from PCR tests, viral 
clearance of ivermectin with doxycycline was more effective than HCQ 
with azithromycin [142]. 
5.13. Doxycycline 
The anti-inflammatory properties of doxycycline and other compo-
nents of tetracycline has been demonstrated for several inflammatory 
airway diseases such as ARDS. Doxycycline (a semisynthetic derivative 
of tetracycline) would seem to be a valid alternative to azithromycin. In 
fact, in addition to its well-defined antibiotic effects (bacteriostatic ac-
tion by inhibition of bacterial protein synthesis), in vitro studies have 
shown that doxycycline has anti-inflammatory effects at low 
(20–40 mg/day) and high (100 or 200 mg/day) doses with inhibitory 
action on metalloproteases, in particular MMP-9, which is likely 
required for initial viral entry into the cell. Doxycycline also modulate 
pro-inflammatory cytokines IL-6, IL-8, and TNF-α [62,63]. In addition, 
low-dose doxycycline has been found to inhibit expression of 
CD147/EMMPRIN, which may be necessary for SARS-CoV-2 entry into T 
lymphocytes. Structural analysis demonstrates that doxycycline has the 
potentials to inhibit PLpro and 3CLpro, which both are essential for viral 
replication and lifecycle [143]. 
Given the risks of hydroxychloroquine and azithromycin in combi-
nation, doxycycline could be a better alternative to azithromycin [63]. 
Paul A et al., reported a series of four patients with COVID-19 infection 
and known high-risk pulmonary disease who were placed on standard 
doses of doxycycline for a course between 5 and 14 days. Patients were 
initiated on therapy with doxycycline. A standard antimicrobial dose of 
doxycycline (100 mg twice daily or daily) was administered to four 
patients in this case series. It is difficult to establish a definitive causal 
link between use of doxycycline and accelerated recovery or decreased 
morbidity from SARS-CoV-2 infection in a small case series. The patients 
had a number of high-risk features, predictive of severe disease and 
increased risk of mortality. There was no concomitant use of any other 
antibiotics, antiviral agents, antimalarial drugs, zinc, or any supple-
ments postulated to be beneficial in therapy for SARS-CoV-2 in these 
four patients. These reported cases were the first correlative relationship 
between doxycycline and potential reduction of severity of symptoms in 
COVID-19 patients. Despite the safety of doxycycline, the general use of 
this drug is not recommended for the treatment of COVID-19 patients, 
unless under the direct guidance and supervision of a physician [143]. 
5.14. Corticosteroids and non-steroidal anti-inflammatory drugs 
The role of corticosteroids for treating COVID-19 is controversial. 
The prescription of corticosteroids in primary and secondary hemo-
phagocytic lymphohistiocytosis (HLH) syndrome and treatment of 
inflammation associated with acute respiratory distress syndrome 
M.S. Mirtaleb et al.                                                                                                                                                                                                                             
Biomedicine & Pharmacotherapy 138 (2021) 111518
9
(ARDS) has led to the application of these drugs for treating COVID-19 
[60]. There is currently no conclusive evidence for the use of 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for treatingthe pa-
tients with COVID-19, whereas corticosteroids are regarded useful in the 
early acute stages of the infection [144]. Corticosteroids can reduce 
inflammatory responses in ARDS; however, the side effects of NSAIDs, 
including the possibility of secondary infections and impairment of viral 
clearance can exclude them from treatment options [144,145]. 
6. Immunotherapy of COVID-19 
In immunotherapy, immune system components are used to fight the 
pathogenic agent. Immunotherapy has provided an appropriate 
response for treating cancer and viral infections. Meanwhile, a couple of 
challenges for treating patients with COVID-19, including dysfunctional 
viral immune response and severe inflammation should be considered. 
Strengthening the immune system using immune-boosting substances 
has benefits in COVID-19 treatment. The development of new immu-
nosuppressive therapies for targeting viral infections and modifying 
dysfunctional immune responses could improve the clinical outcome of 
patients with COVID-19. This new approach has been dubbed as 
"COVID-19 immunotherapy", which is one of the new treatment ap-
proaches with a variety of potentials. Several methods such as plasma 
therapy and cytokine therapy can be used as COVID-19 immunothera-
peutic strategies. 
6.1. Plasma therapy 
As newer antibiotics, antivirals, and vaccines emerged, the use of 
convalescent serum or plasma as a frontline therapy decreased (149). 
The sera of the infection recovered patients contain plenty of anti-
bodies against the pathogens. In this treatment method, the patient’s 
serum is infused to the recently infected patient with the same pathogen, 
so that the specific antibodies neutralize the pathogen in the recipient 
[146]. 
During the outbreak of Ebola virus in 2014 and SARS in 2002, plasma 
therapy was proposed as an experimental treatment against these viral 
infections [147–149]. Some evaluations were performed to analyze the 
clinical effectiveness of convalescent plasma, serum, or hyperimmune 
immunoglobulin for the treatment of severe viral acute respiratory in-
fections including those due to SARS coronavirus, Spanish influenza A 
(H1N1), avian influenza A (H5N1), and pandemic influenza A (H1N1) in 
2009 [118]. In all cases, hyperimmune immunoglobulin was able to 
demonstrate a statistically significant reduction in the odds of mortality 
among those who were treated with convalescent plasma or serum 
[151]. During SARS-CoV infection, it was thought that convalescent 
plasma improve the outcome of infected patients. Previous studies on 
patients with SARS-CoV infection suggested that convalescent plasma 
may be useful for patients with SARS so showed improvements in sur-
vival and resulted in a shorter hospital stay. A protocol for the appli-
cation of convalescent plasma as a therapeutic option for MERS was 
suggested [152]. The recent outbreak of Ebola virus disease (EVD) in 
West Africa has been the worst ever witnessed. By September 9, 2015, a 
total of 28,183 cases and 11,306 deaths had been reported. The high 
case fatality rate (40–60%) highlights the need for effective EVD-specific 
treatments. Such interventions would facilitate the rapid tracing of 
contacts of patients and the implementation of measurements to control 
the spread of an outbreak. The WHO has prioritized the evaluation of 
treatment with convalescent whole blood or plasma derived from pa-
tients who have recovered from EVD. Such treatment has been used 
successfully for other serious infectious diseases with appropriate safe-
guards. In 1995, the largest case series involved eight patients who were 
treated with convalescent whole blood during the Kikwit outbreak of 
EVD that seven patients were survived. However, it was not possible to 
assess whether the low case fatality rate was due to treatment with 
convalescent whole blood or other factors, such as characteristics of the 
patients or the period during the illness at which treatment was given 
[153]. 
In the Pandemic of Covid-19, plasma therapy has been used for 
treating COVID-9 patients [154]. In an initial study, five patients with 
COVID-19 with ARDS underwent plasma therapy and clinical outcomes 
were compared before and after convalescent plasma (CP) transfusion 
The results showed improvement in the patients’ clinical condition 
[154]. Due to the limitations in the sample and the experimental design, 
it is not possible to give a definite opinion about the potential effec-
tiveness of this type of treatment and more clinical observations will be 
needed. 
In a study by Duan et al. in ten severe adult cases, the results showed 
that a dose of 200 mL CP was well tolerated and could significantly 
increase or maintain neutralizing antibodies at a desirable level. This 
treatment was capable of reducing viremia within 7 days. After the 
application of this treatment method, clinical and paraclinical symptoms 
improved rapidly within 3 days. Radiological studies also showed 
varying degrees of absorption of lung lesions within 7 days. According to 
these observations, CP can be expected as a life-saving option in patients 
with severe COVID-19 [155]. 
6.2. Cytokine-based immunotherapy 
Interferon (IFN)-based immunotherapy could be a safe choice for 
multiple sclerosis (MS) patients with mild-to-moderate disease activity 
during the COVID-19 pandemic. At the first stage of viral disease, the 
expression of IFNs could be an appropriate innate immune response to 
the virus. Afterward, the main immune response to the virus is mediated 
by lymphocytes, monocytes, and macrophages. IFNs induce interference 
with viral replication and previous evidence suggests that IFN-β is mildly 
effective in animal models of MERS-CoV whenever used along with 
lopinavir and ritonavir, so the capability of IFN-β for treating COVID-19 
could be a useful investigation [156]. The prescription of IFNs in the 
early stages of COVID-19 can elicit a stronger antiviral response and 
prevent infection spreading to other cells. However, the use of IFNs in 
the severe phase of the immune response can trigger hyperactivation of 
immune response and intensify the cytokine storm. Therefore, this 
treatment is not recommended in the acute phase of infection [157]. 
SARS-CoV-2 inhibits the production of type 1 IFNs by disrupting IFN 
signaling pathways through the inhibition of signal transducers and 
transcription activators such as signal transducer and activator of tran-
scription 1 (STAT1) and Interferon regulatory factor 3 (IRF3). 
IFN production level varies according to age. Due to the low excit-
ability threshold of IFN in children, the mortality rate of COVID-19 
would be lower in children. In contrast, the high excitability threshold 
of IFN results in a higher rate in adults. Inhibition of IFN activity by the 
virus and inadequate production of IFN during the infection is an 
important challenge of the immune response to COVID-19. An in vitro 
study showed that SARS-CoV-2 was more sensitive to treatment with 
IFN-α and -β than many other pathogenic viruses. From a clinical 
perspective, the initial triple treatment of COVID-19 with IFN-β1b, 
lopinavir, and ritonavir has been reported to be more effective than 
lopinavir-ritonavir. The mentioned combination effectively prevents 
infection and reduces disease progression to severe stages. Based on the 
results obtained from in vitro and in vivo experiments, the effectiveness of 
treatment with type I IFNs was approved so IFN-based immunotherapy 
has been considered in clinical trials of patients with COVID-19. 
Numerous clinical trials are evaluating the effects of recombinant 
forms of human type 1 IFNs (IFN-α and -β) for treating early-stage pa-
tients with COVID-19 [119]. 
Type III IFN, also known as IFN-λ, contributes in immune response to 
viral infections. The importance of IFN-λ function in health and disease 
has been difficult to analyze, meanwhile, it seems that the presence of 
IFN-λ is critical to prepare a balance in the antiviral response to SARS- 
CoV-2 in the respiratory tract [158]. IFN-λ activates inflammatory 
transcription factors leading to the stimulation of the Janus kinase (JAK) 
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through the STAT signaling pathway. Based on previous clinical trials 
for application of IFN-λ in chronic viral hepatitis, IFN-λ has been iden-
tified as a candidate for immunotherapy of some viral infections such as 
COVID-19. Accordingly, Peginterferon-λ (PEG-IFN-λ), has been used in 
COVID-19 clinical trials to suppress the viral replication and develop-
ment of cytokine storm [157,158]. 
Cytokine storm as the hallmark of ARDS, is an uncontrolled systemic 
inflammatory response triggered by some immune system cells due to 
the release of proinflammatory cytokines and chemokines in some pa-
tients with COVID-19. In this regard, high expression levels of cytokines 
and chemokines, including IL1-β, IL1RA, IL7, IL8, IL9, IL10, FGF2, GC- 
SF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGFB, TNF-α, and 
VEGFA are observed in the serum of patients with COVID-19 [159]. The 
inability of the immune system to control this condition has led to the 
death of many patients with COVID-19. The immune response features 
in COVID-19 are similar to the immune response in SARS-CoV and 
MERS-CoV infections [8]. 
An urgent attention has been paid to provide suitable control pro-
tocols for SARS-CoV-2; in this regard, the focus has shifted to using IFNs 
to control viral infection [159]. Anti-inflammatory agents have been 
effective in the control of various cytokine storm syndrome cytokines. 
The target of these drugs is usually IL-1, IL-6, IL-18, and IFN-γ. Although, 
there is no definitive drug for treating a cytokine storm in patients with 
COVID-19, the administration of anti-inflammatory agents requires 
further investigation. Meanwhile, the application of anti-IL-6 antibody 
has been suggested for effective blockade of IL-6 and control of ARDS in 
patients with COVID-19 [159]. 
According to the IFN-I therapy studies conducted on the SARS-CoV 
and MERS-CoV infections, type 1 IFNs show high-potential for treating 
patients with COVID-19 [160]. In this regard, IFN-α2b was used as a 
therapeutic agent for treating patients with COVID-19 according to a 
study conducted in Wuhan, China [161]. In this study, 77 hospitalized 
adults with COVID-19 were treated with IFN-α2b (5 mU b.i.d.), or 
arbidol (200 mg t.i.d), or a combination of both pharmaceuticals. He-
matological, biochemical and immunological parameters were evalu-
ated. IFN-α2b therapy, either alone or concomitantly with arbidol, 
significantly reduced the duration of the detection of SARS-CoV-2 virus 
in the upper respiratory tract and also reduced the blood levels of the 
inflammatory markers such as IL-6 and CRP. Referring to the conducted 
studies, IFN could be considered as a pharmaceutical option for treating 
patients with COVID-19 [161]. 
7. Cell therapy 
Cell-based therapies are classified into two major categories, 
including allogeneic and autologous sources. Both categories can be 
applied with a minimum manipulation in clinical purposes. The local 
production for small-scale autologous facilities can be located close to 
patients with dedicated set. One of the major disadvantages of autolo-
gous cell therapy is the cost-effectiveness and inadequacy of target scale 
in the treatment process. The preparation of autologous cell therapies is 
done manually and takes time. Other disadvantages of autologous cell- 
based therapy methods are long cultivation periods, large numbers of 
technicians, and necessity for elevation of contamination risk. The initial 
source of the provided cells in both cell-based technics can be expanded 
using the existing equipment and available technologies for future ap-
plications. Therefore, cell therapy is a cost-effective treatment method 
and performing in the larger cell volumes is more laborious; moreover, 
the cell stability can be a limitation, too [162]. 
7.1. Stem cell therapy 
Nowadays, cell-based therapy methods such as stem cell therapy are 
considered potential therapeutic strategies for treating some severe 
diseases. Due to the superior properties of mesenchymal stem cells 
(MSCs) and their conditioned medium compared to other cellular 
therapies, the application of MSC-based therapy has further expanded in 
the field of cell therapy [163]. 
MSCs are readily available and can be isolated and stored from 
various tissues such as bone marrow and adipose tissue. MSCs are 
multipotent stem cells and can be easily expanded to clinical applica-
tions in a desired period. Therapeutic application of MSCs has been 
documented in several clinical trials. Clinical trials using MSCs have not 
shown any adverse effects in the patients [163]. 
In patients with COVID-19, the cytokine storm occurs after over- 
production of inflammatory agents by the immune system. MSCs con-
trol the release and activity of cytokine in this condition which is pro-
vided through endogenous repair with compensatory properties of the 
stem cell products. 
By intravenous injection of MSCs, the pulmonary environment is 
restored, alveolar epithelial cells are protected, pulmonary fibrosis is 
inhibited and COVID-19 pneumonia is treated. Therefore, MSC-based 
therapy can be a potential novel treatment ideal for clinical trials or at 
least along with other treatment methods for patients with COVID-19 
[163]. 
In a study by Liang et al. on a 65-year-old woman with COVID-19, 
human umbilical cord MSCs (hUCMSCs) were used. The allogenic 
hUCMSCs were given three times (5 × 107 cells each time) with a 3-day 
interval, with daily injection of thymosin α1 and antibiotics. After 
treatment with MSCs, most experimental indicators and computerized 
tomography (CT) images showed an improvement in the inflammation 
and symptoms. The patient was then transferred out of intensive care 
unit (ICU) and the throat swab test for RT-PCR test was reported nega-
tive 4 days later. The results suggested that hUCMSCs could be a po-
tential treatment option alone or in combination with other immune 
modulators for acute patients with COVID-19 [164]. 
In a study by Leng et al., they investigated the effect of MSC trans-
plantation on pneumonia-associated patients with COVID-19. The 
period of treatment lasted for 14 days. Within 2 days post- 
transplantation, the patients’ pulmonary function had improved 
dramatically. After treatment, the CRP level decreased, peripheral 
lymphocyte count was increased, cytokine-secreting immune cells such 
as CXCR3+CD4+ T and CXCR3+CD8+ T cells were over-activated, and 
CXCR3+ natural killer (NK) cells disappeared within 3–6 days. Mean-
while, the group of immunological cells including CD14+, CD11c+, 
CD11bmid, and regulatory dendritic cells (DCs) dramatically increased. 
During the treatment, the level of IL-10 as an immunomodulatory 
cytokine was increased, while, the level of TNF-α was decreased. 
Therefore, intravenous transplantation of MSCs can be a potential and 
safe treatment method against acute pneumonia-associated patients 
with COVID-19 [165]. 
Exosomes are secretory components studied for their similarity to the 
paracrine effect of MCSs for treating various diseases. These 30–150 nm 
nanoparticles are involved in cellular communication and are respon-
sible for transporting many biological materials, including mRNA and 
protein molecules [166]. 
The use of MSC-derived exosomes as cell-free therapeutics offers 
several advantages over their cellular counterparts, including high sta-
bility, low immunogenicity, ease of storage, and ability to cross the 
blood-brain barrier. MSCs-derived exosomes could be a new interven-
tion idea to treat severe conditions of COVID-19 through modulation of 
the immune system and antimicrobials [126]. Finally, controlled ex-
periments are needed to evaluate the possible treatment of COVID-19 
with MSCs, their conditioned medium and MSC-derived exosomes 
[167,168]. 
7.2. NK cell therapy 
NK cells are a subset of innate immunity lymphocytes that comprise 
10− 15% of total peripheral blood leukocytes. They are categorized as 
first-line defense components against viruses. They are naturally acti-
vated during the initial immune response to virus-infected cells and 
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promote the infected cells toward apoptosis [169]. The most distinct 
features of the NK immune response are MHC independence and ready 
availability to combat virally infected cells. Their functionality could be 
enhanced by macrophage-derived cytokines and type I IFNs. Since the 
outbreak of COVID-19, scientists have considered the use of NK cells as 
an effective cell therapy method for treating patients with COVID-19 
[157]. 
The chimeric antigen receptor (CAR) is a genetically engineered re-
ceptor that is widely used for treating various cancers. Engineered NK 
cells expressing CAR molecules can specifically target virus antigen- 
expressing cells. Since NK cells play an important role in antiviral im-
mune response to SARS-CoV-2, CAR-NK engineered cells have been 
proposed as a new approach to the treatment of COVID-19. ACE-2 can be 
a target antigen that can be used to design CAR-NK cells against SARS- 
CoV-2. NCT04324996 is a phase I/II clinical trial study initiated to 
evaluate the efficacy of Universal Off-the-shelf NKG2D-ACE2 CAR-NK 
cells for treating COVID-19 pneumonia [157,170]. 
7.3. DC therapy 
As members of the innate immune system, type 1 DCs (DC-1) exert 
their antiviral immune response by producing IL-6 and IFN, and acting 
as antigen-presenting cells. The application of engineered DCs is mainly 
a hot topic in cancer therapy, however, its application in infectious 
disease is possible, too. DCs may activate NK cells by expressing NKG2D 
[171]. However, the hypersecretion of IL-6 is considered the major 
mechanism that contributes to the progression of respiratory inflam-
mation and lung tissue damage in ARDS. Application of DC-blocking 
agents and using engineered DCs could be considered for inhibition of 
the proinflammatory effects of patients with severe COVID-19 [157]. 
7.4. Macrophage therapy 
Macrophages are categorized into type 1 macrophages (M1) with 
proinflammatory functions, and type 2 macrophages (M2) with anti- 
inflammatory properties. Commonly, these cells could be developed 
from monocytes in the in vitro conditions. Similarly, in the in vivo con-
dition the circulating monocytes enter tissues and differentiate into 
macrophages. During the COVID-19 pandemic, M1 macrophages 
contribute to severe inflammation by secretion of proinflammatory cy-
tokines such as IL-6 and IL-1β. To suppress the hyperinflammatory 
condition, macrophages can be modified in two ways. The first method 
could be the modulation of the M1 macrophages to secrete lower levels 
of proinflammatory cytokines and the second approach could be the 
application of M2 macrophages to suppress the inflammation of the 
lungs. Considering the application of macrophages for treating COVID- 
19, macrophage therapy could be considered in further studies [157]. 
8. Nanomedicine for treatment of COVID-19 
Recently, nanomedicine has entered all fields of medicine and 
commonly applied as an interdisciplinary method for differential diag-
nosis and imaging. Nano-dimensional biomolecules such as polymeric 
nanoparticles, liposomes, nanosurfactants, nanocrystals and protein 
nanoparticles have been used as carriers to aid drug delivery. The di-
versity and variety of nanoparticles, and the interaction of these mate-
rials with biological tissues and molecules has extended their 
applications in medicine. Theoretically, these particles can effectively 
inactivate the virus by preventing it’s attachment to the host cell. 
Blockade of virus surface proteins by targeted nanoparticles, especially 
those expressed by the virus, can reduce the burden of the virus [172]. 
Metal nanoparticles are capable of preventing viral attachment to the 
cell surface and inhibit their entry into the host cell, thus impeding virus 
replication following their entrance. These findings are based on the 
reaction of nanoparticles consisting of titanium (Ti), silver (Ag), gold 
(Au) and zinc (Zn) against HIV, smallpox, influenza, herpes simplex, 
respiratory syncytial virus, transmissible gastrointestinal virus, and zika 
virus. The mechanism of action is based on the binding of nanoparticles 
to the viral envelope or its protein, thereby disrupting the interaction of 
the virus with the host cell. The effectiveness of the treatment depends 
on the size, shape and surface charge of the nanoparticles; however, 
safety issues regarding the virus concentration must be taken to prevent 
the cytotoxicity of the host cells. The main limitations of metal nano-
particles against viruses are their lack of specificity and, as a result, can 
cause host cytotoxicity, which can be addressed by organic 
nanoparticles. 
According to above discussions, various antimicrobials such as CQ, 
lopinavir, ritonavir, ribavirin, and remedsivir have been tested in clin-
ical trials for COVID-19 and have shown promising results. Antimicro-
bial nanocapsules may also help in the development of safe treatments 
for COVID-19 and other viral diseases [173]. Y Han et al. declared that 
ACE2-Based Peptide Inhibitors could be conjugated to nanoparticles to 
provide better efficacy and consequently applied as antiviral drugs or 
vaccine carriers in COVID-19 [174]. In a study by Lammers et al., 
nanoscale dexamethasone has been described as an effective drug for 
treating COVID-19. The researchers defined the positive effect of the 
nanoformulated dexamethasone for treating diseases such as rheuma-
toid arthritis, inflammatory bowel disease, multiple sclerosis, liver 
fibrosis, wound healing, and cancer. In addition, the nanoformulated 
dexamethasone can be effective for treating patients with COVID-19 
[175,176]. 
For treating patients with COVID-19, a combination of drugs has 
been used as a therapeutic method. This treatment strategy has some 
benefits, including lower dosages of individual drugs with limited side 
effects, achieving multiple and complimenting therapeutic targets, and 
reducing the likelihood of resistance to antibiotics. The nanocarriers are 
believed to be useful in delivering multiple drugs with different physical 
and chemical properties, and can complement the benefits of simulta-
neous drug delivery [177,178]. The flexibility provided by various 
nanomaterials and manufacturing techniques allows the design of drug 
compounds loaded on nanocarriers with excellent control over the 
maintenance of synergistic drug ratios, pharmacokinetic overlap, and 
reduction of combined side effects [23]. 
9. Conclusion 
Since the emergence of COVID-19 in December 2020, many aca-
demic groups and pharmaceutical companies focused their efforts and 
budgets on designing of the pharmaceutical compounds for treatment 
and production of various forms of anti-COVID-19 vaccines. Although 
some pharmaceutical companies such as Pfizer-BioNTech, Moderna, and 
AstraZeneca reported the production of anti-COVID-19 vaccines with 
different definitive immunogenicity percentages [179], the immunoge-
nicity of vaccines does not cover all the global population and the 
elimination of COVID-19 by vaccination may be far from access of WHO 
and governments for next years. Therefore, accessibility to the potential, 
safe, and efficient COVID-19-specific drugs accessible to all geographic 
regions and lower-income economies would be urgent planes to combat 
against COVID-19 in parallel with prevention strategies such as vacci-
nation. The best recommendation for treatment of COVID-19 patients is 
to utilize an efficient present antiviral drug accompany with 
anti-inflammatory and anti-coagulant agents till discovery of a 
SARS-CoV-2-specific drug. To reach the ultimate target, regarding the 
elimination of COVID-19, researchers from all nationalities and phar-
maceutical companies accompany with WHO and charity foundations 
must be joined together and share their experiences on drug designing 
for treatment of COVID-19. 
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A. Montgomery, A. Hogg, D. Babusis, M.O. Clarke, J.E. Spahn, L. Bauer, S. Sellers, 
D. Porter, J.Y. Feng, T. Cihlar, R. Jordan, M.R. Denison, R.S. Baric, Comparative 
therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and 
interferon beta against MERS-CoV, Nat. Commun. 11 (1) (2020) 1–14. 
[91] M. Hurst, D. Faulds, Lopinavir, Drugs 60 (6) (2000) 1371–1379. 
[92] A.H. De Wilde, D. Jochmans, C.C. Posthuma, J.C. Zevenhoven-Dobbe, S. van 
Nieuwkoop, T.M. Bestebroer, B.G. van den Hoogen, J. Neyts, E.J. Snijder, 
Screening of an FDA-approved compound library identifies four small-molecule 
inhibitors of Middle East respiratory syndrome coronavirus replication in cell 
culture, Antimicrob. Agents Chemother. 58 (8) (2014) 4875–4884. 
[93] C.M. Chu, Role of lopinavir/ritonavir in the treatment of SARS: initial virological 
and clinical findings, Thorax 59 (3) (2004) 252–256. 
[94] M. Boffito, I. Arnaudo, R. Raiteri, S. Bonora, A. Sinicco, A. Di Garbo, H. 
E. Reynolds, P.G. Hoggard, D.J. Back, G.D. Perri, Clinical use of lopinavir/ 
ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics, 
Aids 16 (15) (2002) 2081–2083. 
[95] F. Chen, K.H. Chan, Y. Jiang, R.Y.T. Kao, H.T. Lu, K.W. Fan, V.C.C. Cheng, W.H. 
W. Tsui, I.F.N. Hung, T.S.W. Lee, In vitro susceptibility of 10 clinical isolates of 
SARS coronavirus to selected antiviral compounds, J. Clin. Virol. 31 (1) (2004) 
69–75. 
[96] X. Ye, et al., Clinical efficacy of lopinavir/ritonavir in the treatment of 
Coronavirus disease 2019, Eur. Rev. Med. Pharmacol. Sci. 24 (6) (2020) 
3390–3396. 
M.S. Mirtaleb et al.                                                                                                                                                                                                                             
Biomedicine & Pharmacotherapy 138 (2021) 111518
14
[97] R. Hong, et al., Clinical characterization and risk factors associated with cytokine 
release syndrome induced by COVID-19 and chimeric antigen receptor T-cell 
therapy, Bone Marrow Transplant. (2020) 1–11. 
[98] J.S. Khalili, H. Zhu, N.S.A. Mak, Y. Yan, Y. Zhu, Novel coronavirus treatment with 
ribavirin: groundwork for an evaluation concerning COVID-19, J. Med. Virol. 92 
(7) (2020) 740–746. 
[99] L.J. Stockman, R. Bellamy, P. Garner, SARS: systematic review of treatment 
effects, PLoS Med. 3 (9) (2006), e343. 
[100] M.E. Morra, L. Van Thanh, M.G. Kamel, A.A. Ghazy, A.M.A. Altibi, L.M. Dat, T.N. 
X. Thy, N.L. Vuong, M.R. Mostafa, S.I. Ahmed, S.S. Elabd, S. Fathima, T. Le Huy 
Vu, A.S. Omrani, Z.A. Memish, K. Hirayama, N.T. Huy, Clinical outcomes of 
current medical approaches for Middle East respiratory syndrome: a systematic 
review and meta-analysis, Rev. Med. Virol. 28 (3) (2018), e1977. 
[101] Y.M. Arabi, S. Shalhoub, Y. Mandourah, F. Al-Hameed, A. Al-Omari, E. Al Qasim, 
J. Jose, B. Alraddadi, A. Almotairi, K. Al Khatib, A. Abdulmomen, I. Qushmaq, A. 
A. Sindi, A. Mady, O. Solaiman, R. Al-Raddadi, K. Maghrabi, A. Ragab, G.A. Al 
Mekhlafi, H.H. Balkhy, A. Al Harthy, A. Kharaba, J.A. Gramish, A.M. Al-Aithan, 
A. Al-Dawood, L. Merson, F.G. Hayden, R. Fowler, Ribavirin and interferon 
therapy for critically ill patients with middle east respiratory syndrome: a 
multicenter observational study, Clin. Infect. Dis. 70 (9) (2020) 1837–1844. 
[102] I.F.-N. Hung, K.C. Lung, E.Y.K. Tso, R. Liu, T.W.H. Chung, M.Y. Chu, Y.Y. Ng, 
J. Lo, J. Chan, A.R. Tam, H.P. Shum, V. Chan, A.K.L. Wu, K.M. Sin, W.S. Leung, W. 
L. Law, D.C. Lung, S. Sin, P. Yeung, C.C.Y. Yip, R.R. Zhang, A.Y.F. Fung, E.Y. 
W. Yan, K.H. Leung, J.D. Ip, A.W.H. Chu, W.M. Chan, A.C.K. Ng, R. Lee, K. Fung, 
A. Yeung, T.C. Wu, J.W.M. Chan, W.W. Yan, W.M. Chan, J.F.W. Chan, A.K.W. Lie, 
O.T.Y. Tsang, V.C.C. Cheng, T.L. Que, C.S. Lau, K.H. Chan, K.K.W. To, K.Y. Yuen, 
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the 
treatment of patients admitted to hospital with COVID-19: an open-label, 
randomised, phase 2 trial, Lancet 395 (10238) (2020) 1695–1704. 
[103] L. Zhang, X. Feng, D. Zhang, C. Jiang, H. Mei, J. Wang, C. Zhang, H. Li, X. Xia, 
S. Kong, J. Liao, H. Jia, X. Pang, Y. Song, Y. Tian, B. Wang, C. Wu, H. Yuan, 
Y. Zhang, Y. Li, W. Sun, Y. Zhang, S. Zhu, S. Wang, Y. Xie, S. Ge, L. Zhang, Y. Hu, 
M. Xie, Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, 
China: prevalence, risk factors, and outcome, Circulation 142 (2) (2020) 
114–128. 
[104] C. Castilletti, L. Bordi, E. Lalle, G. Rozera, F. Poccia, C. Agrati, I. Abbate, M. 
R. Capobianchi, Coordinate induction of IFN-α and-γ by SARS-CoV also in the 
absence of virus replication, Virology 341 (1) (2005) 163–169. 
[105] S. Shi, J. PENG, Y. LI, C. QIN, G. LIANG, L. XU, Y. YANG, J. WANG, Q. SUN, The 
expression of membrane protein augments the specific responses induced by 
SARS-CoV nucleocapsid DNA immunization, Mol. Immunol. 43 (11) (2006) 
1791–1798. 
[106] C.-T.K. Tseng, L.A. Perrone, H. Zhu, S. Makino, C.J. Peters, Severe acute 
respiratory syndrome and the innate immune responses: modulation of effector 
cell function without productive infection, J. Immunol. 174 (12) (2005) 
7977–7985. 
[107] P. Luo, Y. Liu, L. Qiu, X. Liu, D. Liu, J. Li, Tocilizumab treatment in COVID-19: a 
single center experience, J. Med. Virol. 92 (7) (2020) 814–818. 
[108] S.K. Alzghari, V.S. Acuña, Supportive treatment with tocilizumab for COVID-19: a 
systematic review, J. Clin. Virol. 127 (2020), 104380. 
[109] J. Stebbing, A. Phelan, I. Griffin, C. Tucker, O. Oechsle, D. Smith, P. Richardson, 
COVID-19: combining antiviral and anti-inflammatory treatments, Lancet Infect. 
Dis. 20 (4) (2020) 400–402. 
[110] U. Danilczyk, J.M. Penninger, Angiotensin-converting enzyme II in the heart and 
the kidney, Circ. Res. 98 (4) (2006) 463–471. 
[111] S.-Y. Pu, F. Xiao, S. Schor, E. Bekerman, F. Zanini, R. Barouch-Bentov, C. 
M. Nagamine, S. Einav, Feasibility and biological rationale of repurposing 
sunitinib and erlotinib for dengue treatment, Antivir. Res. 155 (2018) 67–75. 
[112] F.J. Sorrell, M. Szklarz, K.R. Abdul Azeez, J.M. Elkins, S. Knapp, Family-wide 
structural analysis of human numb-associated protein kinases, Structure 24 (3) 
(2016) 401–411. 
[113] R.A. Mesa, Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of 
myeloproliferative neoplasms and psoriasis, IDrugs 13 (6) (2010) 394. 
[114] R. Channappanavar, C. Fett, M. Mack, P.P. Ten Eyck, D.K. Meyerholz, S. Perlman, 
Sex-based differences in susceptibility to severe acute respiratory syndrome 
coronavirus infection, J. Immunol. 198 (10) (2017) 4046–4053. 
[115] F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, J. Xiang, Y. Wang, B. Song, X. Gu, 
L. Guan, Y. Wei, H. Li, X. Wu, J. Xu, S. Tu, Y. Zhang, H. Chen, B. Cao, Clinical 
course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, 
China: a retrospective cohort study, Lancet 395 (10229) (2020) 1054–1062. 
[116] S. Chaplin, Baricitinib: a new oral treatment for rheumatoid arthritis, Prescriber 
28 (6) (2017) 44–46. 
[117] D. Praveen, P.R. Chowdary, M.V. Aanandhi, Janus kinase inhibitor baricitinib is 
not an ideal option for management of COVID-19, Int. J. Antimicrob. Agents 55 
(2020), 105967. 
[118] H. Khorramdelazad, M.H. Kazemi, A. Najafi, M. Keykhaee, R. Zolfaghari Emameh, 
R. Falak, Immunopathological similarities between COVID-19 and influenza: 
investigating the consequences of Co-infection, Microb. Pathog. 152 (2021), 
104554. 
[119] D. Siegel, H.C. Hui, E. Doerffler, M.O. Clarke, K. Chun, L. Zhang, S. Neville, 
E. Carra, W. Lew, B. Ross, Q. Wang, L. Wolfe, R. Jordan, V. Soloveva, J. Knox, 
J. Perry, M. Perron, K.M. Stray, O. Barauskas, J.Y. Feng, Y. Xu, G. Lee, A. 
L. Rheingold, A.S. Ray, R. Bannister, R. Strickley, S. Swaminathan, W.A. Lee, 
S. Bavari, T. Cihlar, M.K. Lo, T.K. Warren, R.L. Mackman, Discovery and synthesis 
of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin-4-amino] adenine C- 
nucleoside (GS-5734) for the treatment of ebola and emerging viruses, J. Med. 
Chem. 60 (2017) 1648–1661. 
[120] J.-H. Yoo, Uncertainty about the efficacy of Remdesivir on COVID-19, J. Korean 
Med. Sci. 35 (23) (2020), e221. 
[121] W.-C. Ko, J.M. Rolain, N.Y. Lee, P.L. Chen, C.T. Huang, P.I. Lee, P.R. Hsueh, 
Arguments in favour of remdesivir for treating SARS-CoV-2 infections, Int. J. 
Antimicrob. Agents 55 (4) (2020), 105933. 
[122] E. Tchesnokov, J. Feng, D. Porter, M. Götte, Mechanism of inhibition of Ebola 
virus RNA-dependent RNA polymerase by remdesivir, Viruses 11 (4) (2019) 326. 
[123] A.K. Singh, A. Singh, R. Singh, A. Misra, Remdesivir in COVID-19: a critical 
review of pharmacology, pre-clinical and clinical studies, Diabetes Metab. Syndr. 
Clin. Res. Rev. 14 (4) (2020) 641–648. 
[124] W. Guan, Z. Ni, Y. Hu, W. Liang, C. Ou, J. He, L. Liu, H. Shan, C. Lei, D.S.C. Hui, 
B. Du, L. Li, G. Zeng, K.Y. Yuen, R. Chen, C. Tang, T. Wang, P. Chen, J. Xiang, 
S. Li, J. Wang, Z. Liang, Y. Peng, L. Wei, Y. Liu, Y. Hu, P. Peng, J. Wang, J. Liu, 
Z. Chen, G. Li, Z. Zheng, S. Qiu, J. Luo, C. Ye, S. Zhu, N. Zhong, Clinical 
characteristics of coronavirus disease 2019 in China, N. Engl. J. Med. 382 (18) 
(2020) 1708–1720. 
[125] J.A. Al-Tawfiq, A.H. Al-Homoud, Z.A. Memish, Remdesivir as a possible 
therapeutic option for the COVID-19, Travel Med. Infect. Dis. 34 (2020), 101615. 
[126] M. Wang, R. Cao, L. Zhang, Remdesivir and chloroquine effectively inhibit the 
recently emerged novel coronavirus (2019 nCoV) in vitro, Cell Res. 30 (2019) 
269–271. 
[127] M. Jacobs, A. Rodger, D.J. Bell, S. Bhagani, I. Cropley, A. Filipe, R.J. Gifford, 
S. Hopkins, J. Hughes, F. Jabeen, I. Johannessen, D. Karageorgopoulos, 
A. Lackenby, R. Lester, R.S.N. Liu, A. MacConnachie, T. Mahungu, D. Martin, 
N. Marshall, S. Mepham, R. Orton, M. Palmarini, M. Patel, C. Perry, S.E. Peters, 
D. Porter, D. Ritchie, N.D. Ritchie, R.A. Seaton, V.B. Sreenu, K. Templeton, 
S. Warren, G.S. Wilkie, M. Zambon, R. Gopal, E.C. Thomson, Late Ebola virus 
relapse causing meningoencephalitis: a case report, Lancet 388 (10043) (2016) 
498–503. 
[128] Y.N. Lamb, Remdesivir: first approval, Drugs 80 (2020) 1355–1363. 
[129] J. Grein, N. Ohmagari, D. Shin, G. Diaz, E. Asperges, A. Castagna, T. Feldt, 
G. Green, M.L. Green, F.X. Lescure, E. Nicastri, R. Oda, K. Yo, E. Quiros-Roldan, 
A. Studemeister, J. Redinski, S. Ahmed, J. Bernett, D. Chelliah, D. Chen, 
S. Chihara, S.H. Cohen, J. Cunningham, A. D’Arminio Monforte, S. Ismail, 
H. Kato, G. Lapadula, E. L’Her, T. Maeno, S. Majumder, M. Massari, M. Mora- 
Rillo, Y. Mutoh, D. Nguyen, E. Verweij, A. Zoufaly, A.O. Osinusi, A. DeZure, 
Y. Zhao, L. Zhong, A. Chokkalingam, E. Elboudwarej, L. Telep, L. Timbs, I. Henne, 
S. Sellers, H. Cao, S.K. Tan, L. Winterbourne, P. Desai, R. Mera, A. Gaggar, R. 
P. Myers, D.M. Brainard, R. Childs, T. Flanigan, Compassionate use of remdesivir 
for patients with severe Covid-19, N. Engl. J. Med. 382 (24) (2020) 2327–2336. 
[130] Y. Furuta, K. Takahashi, M. Kuno-Maekawa, H. Sangawa, S. Uehara, K. Kozaki, 
N. Nomura, H. Egawa, K. Shiraki, Mechanism of action of T-705 against influenza 
virus, Antimicrob. Agents Chemother. 49 (3) (2005) 981–986. 
[131] Y. Furuta, T. Komeno, T. Nakamura, Favipiravir (T-705), a broad spectrum 
inhibitor of viral RNA polymerase, Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 93 (7) 
(2017) 449–463. 
[132] D. Sissoko, C. Laouenan, E. Folkesson, A.B. M’Lebing, A.H. Beavogui, S. Baize, A. 
M. Camara, P. Maes, S. Shepherd, C. Danel, S. Carazo, M.N. Conde, J.L. Gala, 
G. Colin, H. Savini, J.A. Bore, F. Le Marcis, F.R. Koundouno, F. Petitjean, M. 
C. Lamah, S. Diederich, A. Tounkara, G. Poelart, E. Berbain, J.M. Dindart, 
S. Duraffour, A. Lefevre, T. Leno, O. Peyrouset, L. Irenge, N. Bangoura, R. Palich, 
J. Hinzmann, A. Kraus, T.S. Barry, S. Berette, A. Bongono, M.S. Camara, 
V. Chanfreau Munoz, L. Doumbouya, Souley Harouna, P.M. Kighoma, F. 
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